preventie van thrombose prevention of thrombosis thrombosis prophylaxis
Conditions
Interventions
In one group of patients Heparin infusion will be stopped simultaneous to
stopping of CVVH.
In the other group of patients UFH infusion will be reduced to 50% from the
previous infusion rate. After
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients scheduled to stop treatment with CVVH because they no longer require it (physicians discretion / local protocol) Age >18 years At least 48 hours of CVVH treatment with concomitant continuous infusion of UFH At least 36 hours of continuous UFH infusion in the last 48 hours prior to inclusion
Exclusion criteria
Exclusion criteria: Patients with known coagulation disorders Patients receiving any anti-coagulant treatment for reasons other than CVVH
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Markers of coagulation and fibrinolysis: aPTT, anti-Xa, factor VII/VIIa, TF, TFPI-antigen, TFPI activity, protein C / activated protein C, prothrombine fragment 1.2, TATc, ETP (Endogenous Thrombin Potential), Fibrin monomers, soluble thrombomodulin, PAPc, PAI. | — |
Secondary
| Measure | Time frame |
|---|---|
| - | — |
Countries
Netherlands
Outcome results
None listed